Engineering D-helix of antithrombin in alpha-1-proteinase inhibitor confers antiinflammatory properties on the chimeric serpin

Summary

Antithrombin (AT) is a heparin-binding serpin in plasma which regulates the proteolytic activity of procoagulant proteases of the clotting cascade. In addition to being an anticoagulant, AT also exhibits antiinflammatory activities when it binds to cell surface heparan sulfate proteoglycans (HSPGs) on the endothelium via its basic residues of D-helix to elicit intracellular signalling responses. By contrast to AT, α₁-proteinase inhibitor (α₁-PI) is a non-heparin-binding serpin that exhibits very slow reactivity with coagulation proteases and possesses no HSPG-dependent antiinflammatory properties. To determine whether the antiinflammatory signaling specificity of AT can be transferred to α₁-PI, we replaced the D-helix of human α₁-PI with the corresponding sequence of human AT and expressed the chimeric serpin α₁-PI/D-helix) in a bacterial expression system. High molecular weight heparin bound to α₁-PI/D-helix and accelerated the inhibition of thrombin by the serpin mutant by a template mechanism reminiscent of the cofactor effect of heparin on inhibition of thrombin by AT. Like AT, α₁-PI/D-helix exhibited antiinflammatory properties in both cellular and animal models. Thus, α₁-PI/D-helix inhibited the barrier-disruptive effect of proinflammatory cytokines and inhibited the activation of nuclear factor-kB transcription factor in lipopolysaccharide-stimulated endothelial cells by a concentration-dependent manner. Furthermore, the chimeric serpin reduced lipopolysaccharide-mediated lethality, elicited a vascular protective effect and inhibited infiltration of activated leukocytes to the peritoneal cavity of mice in an HMGB1-mediated inflammatory model. These results suggest that grafting the D-helix of AT to α₁-PI confers antiinflammatory properties on the serpin and that the chimeric serpin may have therapeutic utility for treating inflammatory disorders.

Keywords

Antithrombin - coagulation inhibitors - endothelial cells - inflammation - SERPINs

^* L. Yang and P. Dinarvand made equal contribution to this study.

• References

• 1 Olson ST, Swanson R, Raub-Segall E. et al. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin. Thromb Haemost 2004; 92: 929-939.
• 2 Olson ST, Gettins PG. Regulation of proteases by protein inhibitors of the serpin superfamily. Prog Mol Biol Transl Sci 2011; 99: 185-240.
• 3 Jin L, Abrahams J, Skinner R. et al. The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci USA 1997; 94: 14683-14688.
• 4 Pratt CW, Whinna HC, Church FC. A comparison of three heparin-binding serine proteinase inhibitors. J Biol Chem 1992; 267: 8795-8801.
• 5 Huntington JA, Read RJ, Carrell RW. Structure of a serpin-protease complex shows inhibition by deformation. Nature 2000; 407: 923-926.
• 6 Belzar KJ, Zhou A, Carrell RW. et al. Helix D elongation and allosteric activation of antithrombin. J Biol Chem 2002; 277: 8551-8558.
• 7 Dementiev A, Dobó J, Gettins PG. Active site distortion is sufficient for proteinase inhibition by serpins: structure of the covalent complex of alpha1-proteinase inhibitor with porcine pancreatic elastase. J Biol Chem 2006; 281: 3452-3457.
• 8 Rezaie AR. Calcium enhances heparin catalysis of the antithrombin-factor Xa reaction by a template mechanism. Evidence that calcium alleviates Gla domain antagonism of heparin binding to factor Xa. J Biol Chem 1998; 273: 16824-16827.
• 9 Olson ST, Björk I, Sheffer R. et al. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 1992; 267: 12528-12538.
• 10 Mizutani A, Okajima K, Uchiba M. et al. Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production. Blood 2003; 101: 3029-3026.
• 11 Dunzendorfer S, Kaneider N, Rabensteiner A. et al. Cell-surface heparan sulfate proteoglycan-mediated regulation of human neutrophil migration by the serpin antithrombin III. Blood 2001; 97: 1079-1085.
• 12 Bae JS, Rezaie AR. Mutagenesis studies toward understanding the intracellular signalling mechanism of antithrombin. J Thromb Haemost 2009; 07: 803-810.
• 13 Marcum JA, Rosenberg RD. Anticoagulantly active heparin-like molecules from the vascular tissue. Biochemistry 1984; 23: 1730-1737.
• 14 Minnema MC, Chang ACK, Jansen PM. et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 2000; 95: 1117-1123.
• 15 Wiedermann CJ, Hofmann JN, Juers M. et al. for the KyberSept Investigators. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: Efficacy and safety. Crit Care Med. 2006 34. 285-292.
• 16 Wang J, Wang Y, Wang J. et al. Antithrombin is protective against myocardial ischemia and reperfusion injury. J Thromb Haemost 2013; 11: 1020-1028.
• 17 Travis J, Salvesen GS. Human plasma proteinase inhibitors. Ann Rev Biochem 1983; 52: 655-709.
• 18 Elliot PR, Abrahams JP, Lomas DA. Wild-type α1-antitrypsin is in the canonical inhibitory conformation. J Mol Biol 1998; 275: 419-425.
• 19 Al-Omari M, Korenbaum E, Ballmaier M. et al. Acute-phase protein α1-antitrypsin inhibits neutrophil calpain I and induces random migration. Mol Med 2011; 17: 865-874.
• 20 Peterson FC, Gordon NC, Gettins PG. Formation of a noncovalent serpin-proteinase complex involves no conformational change in the serpin. Use of 1H-15N HSQC NMR as a sensitive nonperturbing monitor of conformation. Biochemistry 2000; 39: 11884-11892.
• 21 Dolmer K, Gettins PG. How the serpin α1-proteinase inhibitor folds. J Biol Chem 2012; 287: 12425-12432.
• 22 Huber R, Carrell RW. Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins. Biochemistry 1989; 28: 8951-8966.
• 23 Pannell R, Johnson D, Travis J. Isolation and properties of human plasma alpha-1-proteinase inhibitor. Biochemistry 1974; 13: 5439-5445.
• 24 Yang L, Manithody C, Qureshi SH. et al. Contribution of exosite occupancy by heparin to the regulation of coagulation proteases by antithrombin. Thromb Haemost 2010; 103: 277-283.
• 25 Qureshi SH, Yang L, Rezaie AR. Contribution of the NH2-terminal EGF-do-main of factor IXa to the specificity of intrinsic tenase. Thromb Haemost 2012; 108: 1154-1164.
• 26 Bae JS, Rezaie AR. Activated protein C inhibits high mobility group box 1 signalling in endothelial cells. Blood 2011; 118: 3952-3959.
• 27 Dinarvand P, Hassanian SM, Qureshi SH. et al. Polyphosphate amplifies proinflammatory responses of nuclear proteins through interaction with receptor for advanced glycation end products and P2Y1 purinergic receptor. Blood 2014; 123: 935-945.
• 28 Bae JS, Lee W, Rezaie AR. Polyphosphate elicits pro-inflammatory responses that are counteracted by activated protein C in both cellular and animal models. J Thromb Haemost 2012; 10: 1145-1151.
• 29 He X, Ye J, Esmon CT. et al. Influence of Arginines 93, 97, and 101 of thrombin to its functional specificity. Biochemistry 1997; 36: 8969-8976.
• 30 O’Reilly MS, Pirie-Shepherd S, Lane WS. et al. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999; 285: 1926-1928.
• 31 Zhang W, Chuang YJ, Jin T. et al. Antiangiogenic antithrombin induces global changes in the gene expression profile of endothelial cells. Cancer Res 2006; 66: 5047-5055.
• 32 Zhang W, Swanson R, Izaguirre G. et al. The heparin-binding site of antithrombin is crucial for antiangiogenic activity. Blood 2005; 106: 1621-1628.
• 33 Meagher JL, Olson ST, Gettins PG. Critical role of the linker region between helix D and strand 2A in heparin activation of antithrombin. J Biol Chem 2000; 275: 2698-2704.
• 34 Owen MC, Brennan SO, Lewis JH, Carrell RW. Mutation of antitrypsin to anti-thrombin. alpha 1-antitrypsin Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder. N Engl J Med 1983; 309: 694-698.
• 35 Travis J, Owen M, George P. et al. Isolation and properties of recombinant DNA produced variants of human alpha 1-proteinase inhibitor. J Biol Chem 1985; 260: 4384-4389.
• 36 Hopkins PC, Crowther DC, Carrell RW. et al. Development of a novel recombinant serpin with potential antithrombotic properties. J Biol Chem 1995; 270: 11866-11871.
• 37 Yu SD, Gan JC. The role of sialic acid and galactose residues in determining the survival of human plasma alpha-antitrypsin in the blood circulation. Arch Biochem Biophys 1977; 179: 477-485.